Skip to main content
SpringerLink
Log in

Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Breast cancers frequently metastasize to bone, in a process in which osteoclasts play a major role. Bisphosphonate pamidronate, a specific inhibitor of osteoclasts, has been widely used in the treatment of bone metastasis (BM). In this study, using an animal model of BM, we examined the prophylactic. and treatment effects of pamidronate against BM and clarified the relationships between BM, pamidronate and bone resorption markers such as urinary pyridinoline and deoxypyridinoline.

Methods

Bone metastases were established by inoculating c-SST-2 (spontaneously developed rat mammary adenocarcinoma) cells into the thoracic aorta of 27 rats, which were then divided into three groups of rats: the untreated control group, the pre-treatment group, consisting of rats treated with pamidronate (10 mg/kg) injected subcutaneously a day before tumor inoculation, and the post-treatment group, in which rats were injected with pamidronate a week after tumor inoculation. Three weeks after tumor inoculation, blood and urine samples were collected. The subjects were then sacrificed to harvest the thoracic and lumbar vertebrae for histological examination, consisting of staining with hematoxylin and eosin and tartrate resistant acid phosphatase (TRACP).

Results

The incidence of BM was 70.0%, 44.4% and 37.5% in the control, pre-treatment and post-treatment groups, respectively. Although there was no significant difference among the groups, the rate of BM in the treated groups was lower than that of the control group and no bone destruction was observed in treated rats. The TRACP-stained specimens revealed that there were numerous osteoclasts contributing to the control group tumor burden. The urinary levels of pyridinoline and deoxypyridinoline were reduced by pamidronate.

Conclusions

Our results suggest that pamidronate prevents the development of BM and the destruction of bone associated with BM. Maintaining the values of Pyr and Dpyr at low levels with pamidronate might lead to inhibition of the incidence and development of BM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR: Scanning electron microscopy in bone pathology: review of methods, potential and applications.Scan Electron Microsc: 1537–1554, 1986.

  2. Taube T, Elomaa I, Blomqvist C, Beneton MN, Kanis JA: Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer.Bone 15:161–166, 1994.

    Article  PubMed  CAS  Google Scholar 

  3. Hiraga T, Nakajima T, Ozawa H: Bone resorption induced by a metastatic human melanoma cell line.Bone 16:349–356, 1995.

    Article  PubMed  CAS  Google Scholar 

  4. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites.Cancer Res 51:3059–3061, 1991.

    PubMed  CAS  Google Scholar 

  5. Mundy GR, Yoneda T: Facilitation and suppression of bone metastasis.Clin Orthop: 34–44, 1995.

  6. Ishii S, Kitajima M: Mechanisms of bone metastasis using an animal model.Exp Med 12:1050–1054, 1994.

    CAS  Google Scholar 

  7. Tamura H, Ishii S, Ikeda T, Enomoto K, Imai Y, Kitajima M: A novel animal model for bone metastasis of breast cancer.Proc Am Assoc Cancer Res 34:97, 1993.

    Google Scholar 

  8. Tamura H, Ishii S, Ikeda T, Wada N, Enomoto K, Kitajima M: Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model.Surg Oncol 5:141–147, 1996.

    Article  PubMed  CAS  Google Scholar 

  9. Yuhki N, Hamada J, Kuzumaki N, Takeichi N, Kobayashi H: Metastatic ability and expression of c-fos oncogene in cell clones of a spontaneous rat mammary tumor.Jpn J Cancer Res 77:9–12, 1986.

    PubMed  CAS  Google Scholar 

  10. Katayama I, Yang JP: Reassessment of a cytochemical test for differential diagnosis of leukemic reticuloendotheliosis.Am J clin Pathol 68:268–272, 1977.

    PubMed  CAS  Google Scholar 

  11. Sekine K, Horie H, Hata K, Nanjo M, Sato K, Nishii Y, Yamamoto I, Morita R: Determination of pyridinoline and deoxypyridinoline in urine by high performance liquid chromatography with fluorometric detection.Rinsho Kagaku 21:18–25, 1992 (in Japanese).

    CAS  Google Scholar 

  12. Hall DG, Stoica G: Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system.J Bone Miner Res 9:221–230, 1994.

    PubMed  CAS  Google Scholar 

  13. Kasting GB, Francis MD: Retention of etidronate in human, dog, and rat.J Bone Miner Res 7:513–522, 1992.

    PubMed  CAS  Google Scholar 

  14. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.J Clin Invest 98:698–705, 1996.

    Article  PubMed  Google Scholar 

  15. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.Cancer Res 57:3890–3894, 1997.

    PubMed  CAS  Google Scholar 

  16. Wingen F, Eichmann T, Manegold C, Krempien B: Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.J Cancer Res Clin Oncol 111:35–41, 1986.

    Article  PubMed  CAS  Google Scholar 

  17. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.Cancer Res 55:3551–3557, 1995.

    PubMed  CAS  Google Scholar 

  18. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.J Bone Miner Res 10:1478–1487, 1995.

    Article  PubMed  CAS  Google Scholar 

  19. Senaratne SG, Colston KW: Direct effects of bisphosphonates on breast cancer cells.Breast Cancer Res 4:18–23, 2002.

    Article  PubMed  CAS  Google Scholar 

  20. Fromigue O, Lagneaux L, Body JJ: Bisphosphonates induce breast cancer cell death in vitro.J Bone Miner Res 15:2211–2221, 2000.

    Article  PubMed  CAS  Google Scholar 

  21. Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.Cancer Res 61:4418–4424, 2001.

    PubMed  CAS  Google Scholar 

  22. Wada N, Fujisaki M, Ishii S, Ikeda T, Kitajima M: Evaluation of bone metabolic markers in breast cancer with bone metastasis.Breast Cancer 8:131–137, 2001.

    Article  PubMed  CAS  Google Scholar 

  23. Shimozuma K, Sonoo H, Fukunaga M, Ichihara K, Aoyama T, Tanaka K: Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.J pn J Clin Oncol 29:16–22, 1999.

    Article  CAS  Google Scholar 

  24. Nemoto R, Nakamura I, Nishijima Y, Shiobara K, Shimizu M, Takehara T, Ohta T, Kiyoki M: Serum pyridinoline crosslinks as markers of tumour-induced bone resorption.Br J Urol 80:274–280, 1997.

    PubMed  CAS  Google Scholar 

  25. Wada N, Ishii S, Ikeda T, Enomoto K, Kitajima M: Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.Anticancer Res 19:4515–4521, 1999.

    PubMed  CAS  Google Scholar 

  26. Tamura H, Ishii S, Ikeda T, Enomoto K, Kitajima M: The Relationship between Urinary Pyridinoline, Deoxypyridinoline and Bone Metastasis in a Rat Breast Cancer Model.Breast Cancer 6:23–28, 1999.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Breast Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha Kasniwa, 277-8577, Chiba, Japan

    Noriaki Wada

  2. Department of Surgery, Keio University School of Medicine, Japan

    Noriaki Wada, Tadashi Ikeda & Masaki Kitajima

  3. Department of Surgery, Kawasaki City Hospital, Japan

    Seiichiro Ishii

Authors
  1. Noriaki Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seiichiro Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadashi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaki Kitajima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noriaki Wada.

About this article

Cite this article

Wada, N., Ishii, S., Ikeda, T. et al. Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model. Breast Cancer 11, 282–287 (2004). https://doi.org/10.1007/BF02984550

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02984550

Key words

Abbreviations

Search

Navigation